

Article

Synthesis Optimization of $\text{BaGdF}_5:x\%\text{Tb}^{3+}$ Nanophosphors for Tunable Particle Size

Vladimir Polyakov , Zaira Gadzhimagomedova , Daria Kirsanova  and Alexander Soldatov

The Smart Materials Research Institute, Southern Federal University, 344090 Rostov-on-Don, Russia

* Correspondence: vlpolyakov@sfedu.ru

Abstract: X-ray photodynamic therapy (XPDT) is aimed at the treatment of deep-located malignant tumors thanks to the high penetration depth of X-rays. In XPDT therapy, it is necessary to use materials that effectively absorb X-rays and convert them into visible radiation-nanophosphors. Rare-earth elements, fluorides, in particular, doped BaGdF_5 , are known to serve as efficient nanophosphor. On the other hand, the particle size of nanophosphors has a crucial impact on biodistribution, cell uptake, and cytotoxicity. In this work, we investigated various Tb:Gd ratios in the range from 0.1 to 0.5 and optimized the terbium content to achieve the maximum luminescence under X-ray excitation. The effect of temperature, composition of the ethylene glycol/water solvent, and the synthesis technique (solvothermal and microwave) on the size of the nanophosphors was explored. It was found that the synthesis techniques and the solvent composition had the greatest influence on the averaged particle size. By varying these two parameters, it is possible to tune the size of the nanophosphor particles, which make them suitable for biomedical applications.

Keywords: X-ray photodynamic therapy; cancer treatment; BaGdF_5 nanophosphors; terbium doping; tunable size



Citation: Polyakov, V.; Gadzhimagomedova, Z.; Kirsanova, D.; Soldatov, A. Synthesis Optimization of $\text{BaGdF}_5:x\%\text{Tb}^{3+}$ Nanophosphors for Tunable Particle Size. *Materials* **2022**, *15*, 8559. <https://doi.org/10.3390/ma15238559>

Academic Editor: Mariana Prodana

Received: 28 October 2022

Accepted: 28 November 2022

Published: 1 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

In terms of the number of deaths, malignant tumors rank second among all diseases and are one of the most difficult problems in health care [1–3]. Currently, there is no universal way to cure them without causing severe damage to the body. Existing methods of radiotherapy and chemotherapy, in addition to destroying malignant cells, also destroy healthy cells. Thus, the need to develop alternative and more safety treatment methods is still an important issue. One of these new non-invasive and low-toxicity methods is photodynamic therapy (PDT). The principle action of drugs for PDT is based on the suppression tumor growth by the generation of reactive oxygen species (ROS) [4,5] upon irradiation of a photosensitive substance (photosensitizer) [6–8]. However, the low penetrating power (<1 cm) of near-IR- or UV-radiation imposes significant restrictions on the use of PDT. Tumors that grow deep in the body remain inaccessible. X-rays can be used to increase the depth of penetration, which is a crucial benefit of X-ray photodynamic therapy (XPDT) [9,10]. However, it is necessary to introduce an additional component into the “photosensitizer-ROS” system, which would absorb X-rays and re-emit them into UV-Visible luminescence [11]. One of the most promising and studied are X-ray phosphors based on NaGdF_4 and BaGdF_5 doped with Eu^{3+} , Tb^{3+} , or other lanthanides [12–18]. Its advantages include high chemical stability, resistance to X-ray, and photochemical degradation as well as the ability to fine-tune multicolor luminescence by varying the type and concentration of the dopant ions [19–28]. Furthermore, materials based on BaGdF_5 have been relatively poorly studied, and therefore are of greater interest to researchers. On the other hand, the replacement of Na by heavy Ba in the structure leads to an increase in the content of heavy metal atoms per formula unit without a significant increase in toxicity, which improves the X-ray attenuation capability, thus making it more suitable for X-ray micro-CT.

To obtain the maximum luminescence yield, it is necessary to correctly select the concentration of the dopant. Weak luminescence can be caused either by a too low dopant concentration or by the process of quenching the luminescence at a high concentration [29–32]. Another important criterion for the applicability of composites is their high biocompatibility.

The particle size plays an important role. Too small particles can be quickly filtered out by the body's defense systems without accumulating in the tumor. On the other hand, too large particles are not able to penetrate the biomembranes and accumulate only at the site of their introduction without subsequent penetration into the cells. Nanoparticles (NPs) with a particle size in the range of 50–200 nm are considered optimal for biomedical applications [33]. However, the size of smaller particles (10–15 nm) can be increased by coating them with biocompatible shells such as silica [34–37]. In this case, the porous structure of silica makes it possible to adsorb the photosensitizer molecules.

The size of the resulting nanoparticles can be controlled by varying synthesis parameters such as precursor concentration [38,39], temperature [40,41], choice of solvent [42], reaction time [20], and synthesis method. Temperature variations can affect the rate of reactions and consequently the rate of crystallite growth. The choice of solvent also plays an important role. Recently, the synthesis of nanoparticles in organic solvents, for example, polyols, has become increasingly popular [42,43]. The most optimal solvent in BaGdF₅ synthesis is ethylene glycol (EG). Ethylene glycol acts not only as a solvent, but also as a surfactant. Being adsorbed on the surface, it is able to block the growth of the particles as well as prevent their agglomeration. The addition of water to ethylene glycol can strongly influence the growth of crystallites. This occurs due to the competition of solvents in the coordination sphere of metal ions. Water molecules are a more preferable ligand; therefore, they actively influence the adsorption of ethylene glycol on the surface of the formed particles [44,45]. Techniques for obtaining BaGdF₅ nanoparticles of various sizes using ionic liquids (IL) as structure-driven agents are also known [20,38]. An ionic liquid is a salt in a liquid state. Ionic liquids are environmentally friendly solvents, but they can also act as reagents. For example, IL based on tetrafluoroborates [BF₄][−] can themselves be a source of fluoride ions, which makes it possible to simplify the synthesis process.

To obtain BaGdF₅, solvothermal synthesis is usually used. This technique is well-studied and has good reproducibility. However, the long synthesis time (24 h) is its drawback. We have developed a microwave synthesis technique, which makes it possible to reduce the synthesis time by 10 times [46]. Another important advantage of microwave synthesis over hydrothermal synthesis is not only the reaction rate, but also the uniformity of the reaction volume heating. This allows for the homogenization of the direction of the chemical reactions throughout the volume.

Previously, we studied BaGdF₅ nanoparticles doped with Eu³⁺, obtained by microwave synthesis, coated with silica, and impregnated with methylene blue as a photosensitizer [37]. In this paper, we optimized the Tb³⁺ content to obtain the maximum luminescence yield. We also studied how microwave and hydrothermal techniques, temperature, and various ratios of EG/water affect the particle sizes of the synthesized nanophosphors.

2. Materials and Methods

2.1. Materials

GdCl₃, TbCl₃ · 6H₂O, BaCl₂ · 2H₂O, ethylene glycol, polyethylene glycol (PEG, M = 1500 g/mol), and NH₄F were purchased from Sigma-Aldrich Co. (St Louis, MO, USA).

2.2. Methods

Samples were prepared using a high-temperature autoclave as well as in a microwave CEM Mars6 reactor (CEM Corporation, Matthews, NC, USA). X-ray powder diffraction (XRD) was measured by means of Bruker D2 PHASER using Cu K α radiation ($\lambda = 1.5406 \text{ \AA}$) at 30 kV, 10 mA, and the following parameters: 2 θ range from 5 to 90, step size of 0.01. An FEI Tecnai G2 Spirit BioTWIN was used to perform TEM for imaging of the obtained samples. An accelerating voltage of 80 kV was used. The elemental composition was

analyzed using micro-X-ray fluorescence spectrometer M4 TORNADO (Bruker, Billerica, MA, USA). The X-ray excited optical luminescence (XEOL) signal was detected by using an Agilent Cary Eclipse fluorescence spectrophotometer with the emission slit set to 10 nm and the following parameters of the X-ray tube: voltage 35 kV and current 1.6 mA. Powder samples were deposited on the thin film, which was fixed in a way that results in an angle of 45° between the sample surface and both the X-ray beam and fluorescence detector window.

2.3. Synthesis

2.3.1. Terbium Content Optimization

To optimize the terbium content, microwave synthesis developed by our scientific group was used. According to the procedure [46], samples were prepared with a terbium content of 5, 10, 25, and 50%. Briefly, a 20 mL solution of a barium, gadolinium, and terbium chloride mixture in ethylene glycol (EG) was prepared using sonication (see Table 1). Then, 1.5 g of polyethylene glycol (PEG-1500) was added to the solution and again sonicated until complete dissolution. After that, 10 mL of ammonium fluoride solution in ethylene glycol was added to the chloride solution.

Table 1. Amount of precursors used in the synthesis process.

Sample	BaCl ₂ · 2H ₂ O		GdCl ₃		TbCl ₃ · 6H ₂ O		NH ₄ F	
	mg	mmol	mg	mmol	mg	mmol	mg	mmol
5Tb MW			250.4	0.95	13.3	0.05		
10Tb MW	244.3	1	210.9	0.9	26.5	0.1	203.7	5.5
25Tb MW			197.7	0.75	66.3	0.25		
50Tb MW			131.8	0.5	132.6	0.5		

The resulting mixture was transferred into Teflon ampoules and placed in a CEM Mars6 microwave reactor. The synthesis conditions were as follows: temperature—200 °C, heating time—2 h. After that, the mixture was washed by centrifugation (13,000 × g rpm for 10 min) three times with water. The resulting solution was dried at 60 °C.

2.3.2. Variation of Synthesis Conditions

The synthesis conditions were varied to obtain particles of the maximum size. Variable parameters included the type of synthesis (microwave MW or solvothermal ST), solvent composition (ethylene glycol/water), and temperature. The detailed synthesis conditions are presented in Table 2.

Table 2. The synthesis conditions.

Type of Synthesis	Sample	% EG	Temperature, °C
Microwave (MW)	25Tb MW 100EG 200T	100	200
	25Tb MW 50EG	50	
	25Tb MW 25EG	25	
	25Tb MW 10EG	10	
	25Tb MW 0EG	0	
	25Tb MW 100EG 150T	100	
	25Tb MW 100EG 100T	100	100
Solvothermal (ST)	25Tb ST 100EG 200T	100	200
	25Tb ST 50EG	50	
	25Tb ST 25EG	25	
	25Tb ST 10EG	10	
	25Tb ST 0EG	0	
	25Tb ST 100EG 100T	100	
	25Tb ST 100EG RT	100	RT

3. Results and Discussion

3.1. Terbium Content Optimization

3.1.1. X-Ray Diffraction of BaGdF₅: x%Tb³⁺

The profile analysis was carried out using the Jana2006 program package (version 25/10/2015) [47]. In our previous work [16], it was stated that all synthesized samples crystallized in the single cubic space group Fm-3m (225) (JCPDS card no. 24-0098 [48]). The XRD patterns are shown in Figure 1.




Figure 1. XRD patterns of the BaGdF₅: x%Tb³⁺ samples synthesized by the MW method (where x reported the legend).

The refined (Figures S1 and S2) value of the cell parameters and cell volumes are presented in Table 3 and Figure 2. The profile parameters were refined using the pseudo-Voigt function.

Table 3. Cell parameters of the BaGdF₅: x%Tb³⁺ samples calculated from the full profile analysis in the Jana2006 software and crystal size calculated using the Scherrer equation.

Sample	Expected Tb Content, at. %	Actual Tb Content, at. %	Cell Parameters. Å	Cell Volume. Å ³	Goodness of Fit (GOF)	R-Factor	Crystal Size. nm
5Tb MW	0.71	0.45	5.9310(12)	208.64(7)	1.03	0.1282	8.53
10Tb MW	1.43	1.37	5.9279(14)	208.30(8)	1.12	0.1120	8.87
25Tb MW	3.57	3.78	5.9201(16)	207.49(3)	1.04	0.1546	7.67
50Tb MW	7.14	6.91	5.9034(9)	205.73(5)	0.99	0.1141	10.25

According to the refined values, it can be observed that the doping of the BaGdF₅ crystal structure with Tb³⁺ ions led to the decrease in the cell parameters. This fact can be explained by the analysis of the ionic radius of the doping element. The ionic radii of the hexacoordinated Gd³⁺ and Tb³⁺ were 1.078 and 1.063 Å, respectively [49]. Thus, it can be seen that the Tb³⁺ ions had a smaller ionic radius and, therefore, the increase in the dopant content led to a decrease in the cell parameters (Figure 2). The observed trend confirmed that Tb³⁺ substitutes Gd³⁺ in their lattice positions. The presence of possible side-phases was excluded based on the XRD and XRF data.

Moreover, the Scherrer equation was used for the estimation of the average crystalline size. In this case, shape factor *k* was chosen for spherical particles (*k* = 0.9) because according to the TEM data, synthesized nanoparticles are close to spherical shape (see

Section 3.1.3). The analysis of the full width at half-maximum (FWHM) of the XRD lines showed that for the synthesized 5Tb MW, 10Tb MW, 25Tb MW, and 50Tb MW nanoparticles, the averaged sizes were equal to 8.5, 8.9, 7.7, and 10.3 nm, respectively. The obtained results were in good correspondence to the averaged particle size evaluated explicitly from the TEM images.




Figure 2. Correlation between the actual percentage of doping Tb³⁺ ions and the refined lattice parameter.

3.1.2. X-Ray Fluorescence Measurements of BaGdF₅: x%Tb³⁺

The elemental composition of the BaGdF₅ doped with different initial concentrations ($x = 5, 10, 25, 50\%$) of Tb³⁺ was estimated using X-ray fluorescence (XRF) data. The actual and expected elemental composition percentage of the Ba, Gd, Tb, and F elements for each sample were calculated and reported in Table S1. The obtained results demonstrate that the Tb³⁺ precursor almost entirely reacted during the synthesis involved in the formation of NPs and that BaGd_{1-x}F₅Tb_x stoichiometry is well-established. Some of the notable deviations between the predicted and actual Tb³⁺ content observed for the lowest Tb³⁺ loading were likely due to the presence of a tiny amount of the nonreacted Tb³⁺ precursor as well as an XRF experimental error in determination at a low-concentration level.

3.1.3. Transmission Electron Microscopy (TEM) of BaGdF₅: x%Tb³⁺

The size distribution of the nanoparticles was estimated using the ImageJ program [50] by analyzing the TEM images (Figure 3). The total numbers of the measured nanoparticles were about 600. As a result, it has been shown that for all samples, the nanoparticles were in the range of 5–17 nm. This fact complies with the requirements for nanophosphors as a part of nanocomposites that can be used in XPDT. Moreover, the TEM results are in good agreement with the crystalline size according to the Scherrer analysis (see Section 3.1.1).

3.1.4. X-Ray Excited Optical Luminescence

It is widely known that rare-earth metal ions such as Tb³⁺ doped into a wide range of materials exhibit optical luminescence upon UV–Vis and X-ray radiation [14,28,51,52]. The latter makes it possible to convert ionizing radiation into visible light as part of the XPDT system.




Figure 3. TEM images of (a) 5Tb MW, (b) 10Tb MW, (c) 25Tb MW, and (d) 50Tb MW; Particle size distribution of (e) 5Tb MW, (f) 10Tb MW, (g) 25Tb MW, and (h) 50Tb MW according to the TEM analysis.

The XEOL spectrum (Figure 4) of samples doped with x%Tb showed a spectral shape typical for Tb^{3+} -ions doped into the $BaGdF_5$ structure [14,28]. According to the emission spectrum of x% Tb^{3+} , four strong narrow bands at 490, 545, 586, and 621 nm were ascribed to the electronic transitions from the excited state of 5D_4 to the ground states of 7F_J ($J = 6-3$) [53], as shown in Figure 4b: $^5D_4 \rightarrow ^7F_6$ for $\lambda = 490$ nm, $^5D_4 \rightarrow ^7F_5$ for $\lambda = 545$ nm, $^5D_4 \rightarrow ^7F_4$ for $\lambda = 586$ nm, and $^5D_3 \rightarrow ^7F_3$ for $\lambda = 621$ nm. The dominant peak was the green emission of 544 nm, which is a magnetic dipole transition with $\Delta J = 1$, and was more intense than the other transitions [52–54]. As shown in Figure 4a, we may declare that the optimal actual content of doped Tb^{3+} was equal to 3.78 at. % (i.e., 25Tb). Thus, the 25Tb structure was chosen for further synthesis improvements.




Figure 4. (a) X-ray-excited ($U = 35$ kV, $I = 1.6$ mA) optical luminescence spectra measured for x% of Tb^{3+} ; (b) schematic energy-level diagram showing the processes occurring in $BaGdF_5:Tb^{3+}$.

3.2. Tuning Size of $BaGdF_5: 25Tb^{3+}$ Nanoparticles by Various Synthesis Conditions

3.2.1. X-Ray Diffraction of $BaGdF_5: 25Tb^{3+}$ Obtained by the MW and ST Techniques

The XRD patterns of all MW and ST samples are presented in Figure 5. It can be seen that for solvothermal synthesis in a system containing only ethylene glycol (25Tb ST 100EG) as a solvent, the rate of crystal nucleation was low due to the high viscosity and slow diffusion of the reagents. The system had enough time to heat up before the formation of the crystals started, thus the pure $BaGdF_5$ phase was formed.




Figure 5. XRD patterns of the BaGdF₅: 25%Tb³⁺ prepared with (a) ST and (b) MW synthesis. The impurities of the GdF₃ phase marked with pink circles.

However, the viscosity of the solution dropped, and the reaction rate increased with the addition of water to the system (25Tb ST 25EG and 25Tb ST 50EG). Since there were many more Ba²⁺ and Gd³⁺ ions in the system than Tb³⁺ ions, the statistical probability of the predominant formation of BaF₂, BaGdF₅, and GdF₃ in the first stage was higher than that of their terbium analogues. Then, after the formation of the BaGdF₅ and GdF₃ particles, gadolinium was replaced by terbium. Moreover, based on the standard dissociation energies of the Gd–F bonds (590 kJ/mol [55]) and Tb–F (561 kJ/mol [55]), it can be seen that the process of replacing Gd³⁺ with Tb³⁺ ions is endothermic and therefore proceeds at an elevated temperature. It can be assumed that in the case of hydrothermal synthesis, the heating of the reaction mixture occurs unevenly. These factors, in combination with the slow diffusion of reagents, in particular terbium ions, lead to the fact that the substitution process proceeds more actively in the solvent layer located near the hot walls of the ampoule than in the deep layers. As a result, the small impurities of the GdF₃ phase [56] in the diffraction profiles of these samples can be seen (marked with pink circle at Figure 5a).

In addition, an excess of water in the system (25Tb ST 0EG and 25Tb ST 10EG) led to an even greater drop in the viscosity and facilitated the diffusion of reagents. On the other hand, the thermal conductivity of the solution increased from 0.249 W/m·K for pure ethylene glycol [57] to 0.569 W/m·K for pure water [57]. These factors caused a more uniform reaction over the volume. As a result, the pure BaGdF₅ phase was observed from the XRD (Figure 5a,b).

3.2.2. Transmission Electron Microscopy Measurements of BaGdF₅:25Tb³⁺ Obtained by MW and ST Techniques

The shape, morphology, and size were also studied using transmission electron microscopy (TEM) for the nanoparticles synthesized by two different methods, MW and ST, in two ways: variation in the temperature and EG amount. As seen from the TEM images (Figure 6a, Figure 7a, Figure 8a, Figure 9a) and from the particle size distribution analysis (Figure 6b, Figure 7b, Figure 8b, Figure 9b), all of the 25Tb samples were characterized by the spherical shape of the particles.

The obtained averaged size of the particles (as estimated from TEM) is suitable for medical application. Indeed, such small nanoparticles are known to readily overcome biological barriers [33]. Small capillaries have a diameter of about 3 micrometers, and nanoparticles with a size less than 200 nm can be freely transported through the circulatory system and carry pharmaceutically active substances.




Figure 6. (a) Particle size distribution and $\langle D \rangle$ with the mean size \pm standard deviation; (b) TEM images of 25Tb MW at 100 °C, 150 °C, and 200 °C.




Figure 7. (a) Particle size distribution and $\langle D \rangle$ with the mean size \pm standard deviation; (b) TEM images of 25Tb MW with different contents of EG 0, 10, 25, and 50%.




Figure 8. (a) Particle size distribution and $\langle D \rangle$ with the mean size \pm standard deviation; (b) TEM images of 25Tb ST at room temperature, 100 °C, and 200 °C.




Figure 9. (a) Particle size distribution and $\langle D \rangle$ with the mean size \pm standard deviation; (b) TEM images of 25Tb ST with different contents of EG 0, 10, 25, and 50%.

3.2.3. Microwave Synthesis at Different Temperature and Different Percentage of EG

According to the particle size distribution, the sample synthesized at 200 °C had the most monodisperse character. This once again confirms that the standard procedure developed earlier provided the best result. Another two samples synthesized at 100 °C and 150 °C showed broader peaks and with increasing temperature, the peak shifted toward larger sizes. However, at 200 °C, we observed a peak shift to the small sizes. The

average size of the sample synthesized at 100 °C was 8–9 nm, at 150 °C—10–11 nm, and at 200 °C—6–7 nm (Figure 6).

According to the particle size distribution of the sample synthesized with various shares of EG (Figure 7), almost no change was observed for 25Tb with 0, 10, 25, and 50% EG and the average size for these samples was 20–25 nm. In the case of adding 100% EG, the size of the nanoparticles sharply decreased to 6–8 nm. Similar results were obtained by the team of A. Opalinska for ZnO nanoparticles synthesized by microwave solvothermal synthesis with EG/water solvent [58]. Based on this research, the obtained NPs were characterized by a homogeneous morphology and a narrow distribution of particle sizes.

3.2.4. Solvothermal Synthesis at Different Temperature and Different Percentage of EG

As evident from the particle size distribution, the samples synthesized at room temperature (RT) had an average size of 16–18 nm, at 100 °C it was 10–12 nm, and at 200 °C it was 11–13 nm (Figure 8).

It is easy to see from the particle size distribution of the samples synthesized with x% EG that the 0% EG particles had an average size of 22–25 nm, 10% EG—22–25 nm, 25% EG—34–43 nm, 50% EG—40–58 nm, and 100% EG—9–12 nm (Figure 9). As in the case of microwave syntheses, we observed a sharp decrease in the size of 100% EG nanoparticles as well as a narrower distribution of nanoparticles (i.e., a more monodisperse structure). On this basis, we can conclude that not only the type of heating affects a noticeable shift in the distribution, but also the type of solvent. The wider particle size distribution in the case of 25% EG and 50% EG may correspond to different rates of crystal nucleation and growth in different parts of the reaction space of the autoclave with a simultaneously high solution viscosity and an increase in the reaction rate upon the addition of water. An increase in the water content leads to a decrease in the viscosity and reaction rate. As a result, the difference in the rates of nucleation and the growth of crystallites decreases. Therefore, we could observe a decrease in the proportion of a large fraction of particles in 10% EG and 0% EG samples.

4. Conclusions

The BaGdF₅ nanophosphors with different Tb:Gd ratios ranging from 0.1 to 0.5 were synthesized. Pure BaGdF₅ phases were obtained. According to the XEOL analysis, the sample with the Tb:Gd ratio of 0.25 demonstrated the largest luminescence yield, being an optimal choice for converting X-rays into optical radiation.

Based on the optimal nanophosphor composition, the effect of temperature, the composition of EG/water solvent, and synthesis technique on the size of the obtained particles was next investigated for the samples with 25% of Tb ions. The microwave synthesis at all EG/water compositions makes it possible to obtain smaller particles with a narrower size distribution (7.29 ± 1.48 nm in 100%EG) compared to the solvothermal (13.3 ± 2.96 nm in 100% EG). This was due to the high heating rate and uniform mixture heating. The addition of 50% of water to ethylene glycol led to a sharp increase in the size of the resulting nanoparticles in both the MW and ST methods. Moreover, a further increase in the water content for MW synthesis had practically no effect on the size and width of the distribution of nanoparticles, but differences were noticeable in the case of solvothermal synthesis. For the sample synthesized in a mixture containing 50% EG, the largest nanoparticles with a wide size distribution (49.4 ± 13.3 nm) were observed, which was attributed to the different rates of nucleation and the growth of crystallites in different regions of the reaction volume. Increasing the water content led to a decrease in the nanoparticles' size and a narrower distribution (24.3 ± 6.11 nm in 10%EG). This was due to an increase in the heating rate of the system due to an increase in the thermal conductivity of the solution and a decrease in its viscosity. Temperature variation in both the microwave and solvothermal syntheses did not lead to a noticeable change in the particle size.

Overall, as expected, MW heating produced smaller particles for all of the tested temperatures in comparison with the solvothermal synthesis. Thus, by varying the solvent

composition as well as the method of system heating, we can achieve fine-tuning of the BaGdF₅ nanoparticle sizes.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ma15238559/s1>, Table S1: Calculated initial elemental composition of the BaGdF₅:x%Tb³⁺ samples and the actual elemental composition from the X-ray fluorescence measurements; Figure S1: The diffraction profile and calculated line (upper pattern) and difference curve (lower pattern) of 10Tb (GOF = 1.12); Figure S2: The diffraction profile and calculated line (upper pattern) and difference curve (lower pattern) of 50Tb (GOF = 0.99).

Author Contributions: Conceptualization, methodology, V.P.; Validation, V.P., Z.G. and D.K.; Formal analysis, Z.G. and D.K.; Investigation, V.P., Z.G. and D.K.; Writing—original draft preparation, V.P.; Writing—review and editing, Z.G. and D.K.; Visualization, Z.G. and D.K.; Supervision, data curation, funding acquisition, project administration, A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Russian Science Foundation (grant no. 19-15-00305-II).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All of the data are contained in the manuscript and its Supplementary Materials.

Acknowledgments: The authors team would like to thank Ilya Pankin for his help in measuring XEOL spectra and language editing.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer* **2019**, *144*, 1941–1953. [[CrossRef](#)] [[PubMed](#)]
2. Malvezzi, M.; Carioli, G.; Bertuccio, P.; Boffetta, P.; Levi, F.; La Vecchia, C.; Negri, E. European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann. Oncol.* **2019**, *30*, 781–787. [[CrossRef](#)] [[PubMed](#)]
3. Li, H.; Liu, G.; Wang, J.; Dong, X.; Yu, W. Dual-mode, tunable color, enhanced upconversion luminescence and magnetism of multifunctional BaGdF₅:Ln³⁺ (Ln = Yb/Er/Eu) nanophosphors. *Phys. Chem. Chem. Phys.* **2016**, *18*, 21518–21526. [[CrossRef](#)] [[PubMed](#)]
4. Yang, Y.; Bazhin, A.V.; Werner, J.; Karakhanova, S. Reactive Oxygen Species in the Immune System. *Int. Rev. Immunol.* **2013**, *32*, 249–270. [[CrossRef](#)] [[PubMed](#)]
5. Yang, Y.; Karakhanova, S.; Werner, J.; Bazhin, A.V. Reactive Oxygen Species in Cancer Biology and Anticancer Therapy. *Curr. Med. Chem.* **2013**, *20*, 3677–3692. [[CrossRef](#)]
6. Li, X.; Kwon, N.; Guo, T.; Liu, Z.; Yoon, J. Innovative Strategies for Hypoxic-Tumor Photodynamic Therapy. *Angew. Chem. Int. Ed.* **2018**, *57*, 11522–11531. [[CrossRef](#)]
7. Li, X.; Lee, S.; Yoon, J. Supramolecular photosensitizers rejuvenate photodynamic therapy. *Chem. Soc. Rev.* **2018**, *47*, 1174–1188. [[CrossRef](#)]
8. Pham, T.C.; Nguyen, V.-N.; Choi, Y.; Lee, S.; Yoon, J. Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. *Chem. Rev.* **2021**, *121*, 13454–13619. [[CrossRef](#)]
9. Bulin, A.-L.; Truillet, C.; Chouikrat, R.; Lux, F.; Frochot, C.; Amans, D.; Ledoux, G.; Tillement, O.; Perriat, P.; Barberi-Heyob, M.; et al. X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins. *J. Phys. Chem. C* **2013**, *117*, 21583–21589. [[CrossRef](#)]
10. Larue, L.; Ben Mihoub, A.; Youssef, Z.; Colombeau, L.; Acherar, S.; André, J.C.; Arnoux, P.; Baros, F.; Vermandel, M.; Frochot, C. Using X-rays in photodynamic therapy: An overview. *Photochem. Photobiol. Sci.* **2018**, *17*, 1612–1650. [[CrossRef](#)]
11. Gadzhimagomedova, Z.; Zolotukhin, P.; Kit, O.; Kirsanova, D.; Soldatov, A. Nanocomposites for X-Ray Photodynamic Therapy. *Int. J. Mol. Sci.* **2020**, *21*, 4004. [[CrossRef](#)] [[PubMed](#)]
12. Cui, F.-Z.; Liu, J.-H.; Liu, Y.; Yuan, B.-Y.; Gong, X.; Yuan, Q.-H.; Gong, T.-T.; Wang, L. Synthesis of PEGylated BaGdF₅ Nanoparticles as Efficient CT/MRI Dual-modal Contrast Agents for Gastrointestinal Tract Imaging. *Chin. J. Anal. Chem.* **2020**, *48*, 1004–1011. [[CrossRef](#)]
13. Wang, T.; Jia, G.; Cheng, C.; Wang, Q.; Li, X.; Liu, Y.; He, C.; Chen, L.; Sun, G.; Zuo, C. Active targeted dual-modal CT/MR imaging of VX2 tumors using PEGylated BaGdF₅ nanoparticles conjugated with RGD. *New J. Chem.* **2018**, *42*, 11565–11572. [[CrossRef](#)]

14. Li, H.; Liu, G.; Wang, J.; Dong, X.; Yu, W. $\text{Eu}^{3+}/\text{Tb}^{3+}$ doped cubic BaGdF_5 multifunctional nanophosphors: Multicolor tunable luminescence, energy transfer and magnetic properties. *J. Lumin* **2017**, *186*, 6–15. [[CrossRef](#)]
15. Grzyb, T.; Mrówczyńska, L.; Szczeszak, A.; Śniadecki, Z.; Runowski, M.; Idzikowski, B.; Lis, S. Synthesis, characterization, and cytotoxicity in human erythrocytes of multifunctional, magnetic, and luminescent nanocrystalline rare earth fluorides. *J. Nanoparticle Res.* **2015**, *17*, 1–18. [[CrossRef](#)] [[PubMed](#)]
16. Kirsanova, D.; Polyakov, V.; Butova, V.; Zolotukhin, P.; Belanova, A.; Gadzhimagomedova, Z.; Soldatov, M.; Pankin, I.; Soldatov, A. The Rare-Earth Elements Doping of BaGdF_5 Nanophosphors for X-ray Photodynamic Therapy. *Nanomaterials* **2021**, *11*, 3212. [[CrossRef](#)] [[PubMed](#)]
17. Liu, Y.; Tu, D.; Zhu, H.; Li, R.; Luo, W.; Chen, X. A Strategy to Achieve Efficient Dual-Mode Luminescence of Eu^{3+} in Lanthanides Doped Multifunctional NaGdF_4 Nanocrystals. *Adv. Mater.* **2010**, *22*, 3266–3271. [[CrossRef](#)]
18. Chen, G.; Liu, S.; Law, W.-C.; Wu, F.; Swihart, M.T.; Ågren, H.; Prasad, P.N. Core/Shell $\text{NaGdF}_4:\text{Nd}^{3+}/\text{NaGdF}_4$ Nanocrystals with Efficient Near-Infrared to Near-Infrared Downconversion Photoluminescence for Bioimaging Applications. *ACS Nano* **2012**, *6*, 2969–2977. [[CrossRef](#)]
19. Chouryal, Y.N.; Sharma, R.K.; Ivanovskikh, K.V.; Ishchenko, A.V.; Shi, Q.; Ivanov, V.Y.; Nigam, S.; Pandey, A.; Ghosh, P. Temperature dependent quantum cutting in cubic $\text{BaGdF}_5:\text{Eu}^{3+}$ nanophosphors. *New J. Chem.* **2020**, *45*, 1463–1473. [[CrossRef](#)]
20. Liu, W.; Sun, Q.; Zou, H.; Zhang, X.; Xiao, X.; Shi, Z.; Song, Y. Ionic liquid/ H_2O two-phase synthesis and luminescence properties of $\text{BaGdF}_5:\text{RE}^{3+}$ (RE = Ce/Dy/Eu/Yb/Er) octahedra. *New J. Chem.* **2020**, *45*, 742–750. [[CrossRef](#)]
21. Sengar, M.; Narula, A.K. Luminescence sensitization of Ln^{3+} impurity ions in BaGdF_5 host matrix: Structural investigation, color tunable luminescence and energy transfer. *Opt. Mater.* **2020**, *110*. [[CrossRef](#)]
22. Lee, G.; Struebing, C.; Wagner, B.; Summers, C.; Ding, Y.; Bryant, A.; Thadhani, N.; Shedlock, D.; Star-Lack, J.; Kang, Z. Synthesis and characterization of a $\text{BaGdF}_5:\text{Tb}$ glass ceramic as a nanocomposite scintillator for x-ray imaging. *Nanotechnology* **2016**, *27*, 205203. [[CrossRef](#)] [[PubMed](#)]
23. Guan, H.; Sheng, Y.; Song, Y.; Zheng, K.; Xu, C.; Xie, X.; Dai, Y.; Zou, H. White light-emitting, tunable color luminescence, energy transfer and paramagnetic properties of terbium and samarium doped BaGdF_5 multifunctional nanomaterials. *RSC Adv.* **2016**, *6*, 73160–73169. [[CrossRef](#)]
24. Cao, C.-Y.; Xie, A.; Yu, X.-G. Controlled synthesis and optical properties of $\text{Ce}^{3+}/\text{Tb}^{3+}$ co-doped BaGdF_5 nanocrystals. *Rare Met.* **2014**, *34*, 673–678. [[CrossRef](#)]
25. Yanes, A.; Del-Castillo, J.; Ortiz, E. Energy transfer and tunable emission in $\text{BaGdF}_5:\text{RE}^{3+}$ (RE = Ce, Tb, Eu) nano-glass-ceramics. *J. Alloy. Compd.* **2019**, *773*, 1099–1107. [[CrossRef](#)]
26. Huang, X.; Jiang, L.; Li, X.; He, A. Manipulating upconversion emission of cubic $\text{BaGdF}_5:\text{Ce}^{3+}/\text{Er}^{3+}/\text{Yb}^{3+}$ nanocrystals through controlling Ce^{3+} doping. *J. Alloy. Compd.* **2017**, *721*, 374–382. [[CrossRef](#)]
27. He, F.; Li, C.; Zhang, X.; Chen, Y.; Deng, X.; Liu, B.; Hou, Z.; Huang, S.; Jin, D.; Lin, J. Optimization of upconversion luminescence of Nd^{3+} -sensitized BaGdF_5 -based nanostructures and their application in dual-modality imaging and drug delivery. *Dalton Trans.* **2015**, *45*, 1708–1716. [[CrossRef](#)]
28. Guan, H.; Song, Y.; Zheng, K.; Sheng, Y.; Zou, H. $\text{BaGdF}_5:\text{Dy}^{3+},\text{Tb}^{3+},\text{Eu}^{3+}$ multifunctional nanospheres: Paramagnetic, luminescence, energy transfer, and tunable color. *Phys. Chem. Chem. Phys.* **2016**, *18*, 13861–13873. [[CrossRef](#)]
29. Huignard, A.; Buissette, V.; Franville, A.-C.; Gacoin, T.; Boilot, J.-P. Emission Processes in $\text{YVO}_4:\text{Eu}$ Nanoparticles. *J. Phys. Chem. B* **2003**, *107*, 6754–6759. [[CrossRef](#)]
30. Jorma, H.; Eija, K. Crystal Fields in REOF: Eu^{3+} (RE = La, Gd and Y). *J. Chem. Soc. Faraday Trans.* **1995**, *91*, 1503–1509.
31. King, A.; Singh, R.; Nayak, B.B. Phase and photoluminescence analysis of dual-color emissive Eu^{3+} -doped ZrO_2 nanoparticles for advanced security features in anti-counterfeiting. *Colloids Surfaces A Physicochem. Eng. Asp.* **2021**, *631*, 127715. [[CrossRef](#)]
32. Rezende, M.; Montes, P.J.; Valerio, M.; Jackson, R.A. The optical properties of Eu^{3+} doped BaAl_2O_4 : A computational and spectroscopic study. *Opt. Mater.* **2012**, *34*, 1434–1439. [[CrossRef](#)]
33. Teleanu, D.M.; Chircov, C.; Grumezescu, A.M.; Teleanu, R.I. Neuronanomedicine: An Up-to-Date Overview. *Pharmaceutics* **2019**, *11*, 101. [[CrossRef](#)] [[PubMed](#)]
34. Elmenoufy, A.H.; Tang, Y.; Hu, J.; Xu, H.; Yang, X. A novel deep photodynamic therapy modality combined with CT imaging established via X-ray stimulated silica-modified lanthanide scintillating nanoparticles. *Chem. Commun.* **2015**, *51*, 12247–12250. [[CrossRef](#)] [[PubMed](#)]
35. Hsu, C.-C.; Lin, S.-L.; Chang, C.A. Lanthanide-Doped Core-Shell-Shell Nanocomposite for Dual Photodynamic Therapy and Luminescence Imaging by a Single X-ray Excitation Source. *ACS Appl. Mater. Interfaces* **2018**, *10*, 7859–7870. [[CrossRef](#)] [[PubMed](#)]
36. Chen, H.; Wang, G.D.; Chuang, Y.-J.; Zhen, Z.; Chen, X.; Biddinger, P.; Hao, Z.; Liu, F.; Shen, B.; Pan, Z.; et al. Nanoscintillator-Mediated X-ray Inducible Photodynamic Therapy for In Vivo Cancer Treatment. *Nano Lett.* **2015**, *15*, 2249–2256. [[CrossRef](#)]
37. Gadzhimagomedova, Z.; Polyakov, V.; Pankin, I.; Butova, V.; Kirsanova, D.; Soldatov, M.; Khodakova, D.; Goncharova, A.; Mukhanova, E.; Belanova, A.; et al. BaGdF_5 Nanophosphors Doped with Different Concentrations of Eu^{3+} for Application in X-ray Photodynamic Therapy. *Int. J. Mol. Sci.* **2021**, *22*, 13040. [[CrossRef](#)]
38. Becerro, A.I.; González-Mancebo, D.; Cantelar, E.; Cussó, F.; Stepien, G.; de la Fuente, J.M.; Ocaña, M. Ligand-Free Synthesis of Tunable Size $\text{Ln}:\text{BaGdF}_5$ (Ln = Eu^{3+} and Nd^{3+}) Nanoparticles: Luminescence, Magnetic Properties, and Biocompatibility. *Langmuir* **2016**, *32*, 411–420. [[CrossRef](#)]

39. Kvítek, L.; Pucek, R.; Panáček, A.; Novotný, R.; Hrbáč, J.; Zbořil, R. The influence of complexing agent concentration on particle size in the process of SERS active silver colloid synthesis. *J. Mater. Chem.* **2005**, *15*, 1099–1105. [[CrossRef](#)]
40. Guo, X.; Yan, H.; Zhao, S.; Li, Z.; Li, Y.; Liang, X. Effect of calcining temperature on particle size of hydroxyapatite synthesized by solid-state reaction at room temperature. *Adv. Powder Technol.* **2013**, *24*, 1034–1038. [[CrossRef](#)]
41. Shi, A.-M.; Li, D.; Wang, L.-J.; Li, B.-Z.; Adhikari, B. Preparation of starch-based nanoparticles through high-pressure homogenization and miniemulsion cross-linking: Influence of various process parameters on particle size and stability. *Carbohydr. Polym.* **2011**, *83*, 1604–1610. [[CrossRef](#)]
42. Niederberger, M.; Pinna, N. *Metal Oxide Nanoparticles in Organic Solvents Synthesis, Formation, Assembly and Application*; Springer: London, UK, 2009.
43. Lai, J.; Niu, W.; Luque, R.; Xu, G. Solvothermal synthesis of metal nanocrystals and their applications. *Nano Today* **2015**, *10*, 240–267. [[CrossRef](#)]
44. Wang, H.; Xie, C.; Zeng, D. Controlled growth of ZnO by adding H₂O. *J. Cryst. Growth* **2005**, *277*, 372–377. [[CrossRef](#)]
45. Lian, J.; Liang, Y.; Kwong, F.-L.; Ding, Z.; Ng, D.H. Template-free solvothermal synthesis of ZnO nanoparticles with controllable size and their size-dependent optical properties. *Mater. Lett.* **2012**, *66*, 318–320. [[CrossRef](#)]
46. Kirsanova, D.Y.; Butova, V.V.; Polyakov, V.A.; Zolotukhin, P.V.; Belanova, A.A.; Legostaev, V.M.; Kuchma, E.A.; Gadzhimagomedova, Z.M.; Soldatov, A.V. X-Ray Nanophosphors based on BaGdF₅ for x-ray photodynamic therapy in oncology. *Nanotechnologies Russ.* **2020**, *15*, 105–111. [[CrossRef](#)]
47. Petříček, V.; Dušek, M.; Palatinus, L. Crystallographic Computing System JANA2006: General features. *Z. Für Krist.-Cryst. Mater.* **2014**, *229*, 345–352. [[CrossRef](#)]
48. Gates-Rector, S.; Blanton, T. The Powder Diffraction File: A quality materials characterization database. *Powder Diffr.* **2019**, *34*, 352–360. [[CrossRef](#)]
49. Shannon, R.D. Revised Effective Ionic Radii and Systematic Studies of Interatomic Distances in Halides and Chalcogenides. *Acta Cryst.* **1976**, *32*, 751–767. [[CrossRef](#)]
50. Rueden, C.T.; Schindelin, J.; Hiner, M.C.; DeZonia, B.E.; Walter, A.E.; Arena, E.T.; Eliceiri, K.W. ImageJ2: ImageJ for the next generation of scientific image data. *BMC Bioinform.* **2017**, *18*, 529. [[CrossRef](#)]
51. Yang, D.; Kang, X.; Shang, M.; Li, G.; Peng, C.; Li, C.; Lin, J. Size and shape controllable synthesis and luminescent properties of BaGdF₅:Ce³⁺/Ln³⁺ (Ln = Sm, Dy, Eu, Tb) nano/submicrocrystals by a facile hydrothermal process. *Nanoscale* **2011**, *3*, 2589–2595. [[CrossRef](#)] [[PubMed](#)]
52. Xu, S.; Li, P.; Wang, Z.; Li, T.; Bai, Q.; Sun, J.; Yang, Z. Luminescence and energy transfer of Eu²⁺/Tb³⁺/Eu³⁺ in LiBaBO₃ phosphors with tunable-color emission. *J. Mater. Chem. C* **2015**, *3*, 9112–9121. [[CrossRef](#)]
53. Lee, T.; Luo, L.-Y.; Diau, E.W.-G.; Chen, T.-M.; Cheng, B.M.; Tung, C.-Y. Visible quantum cutting through downconversion in green-emitting K₂GdF₅:Tb³⁺ phosphors. *Appl. Phys. Lett.* **2006**, *89*, 131121. [[CrossRef](#)]
54. Cheng, S.D.; Kam, C.H.; Buddhudu, S. Enhancement of green emission from Tb³⁺:GdOBr phosphors with Ce³⁺ ion co-doping. *Mater. Res. Bull.* **2001**, *31*, 1131–1137. [[CrossRef](#)]
55. Luo, Y.-R. *Comprehensive Handbook of Chemical Bond Energies*; CRC Press: Boca Raton, FL, USA, 2007.
56. Zhao, Q.; Lü, W.; Guo, N.; Jia, Y.; Lv, W.; Shao, B.; Jiao, M.; You, H. Inorganic-salt-induced morphological transformation and luminescent performance of GdF₃ nanostructures. *Dalton Trans.* **2013**, *42*, 6902–6908. [[CrossRef](#)]
57. Bohne, D.; Fischer, S.; Obermeier, E. Thermal, Conductivity, Density, Viscosity, and Prandtl-Numbers of Ethylene Glycol-Water Mixtures. *Ber. Der Bunsenges. Für Phys. Chem.* **1984**, *88*, 739–742. [[CrossRef](#)]
58. Wojnarowicz, J.; Opalińska, A.; Chudoba, T.; Gierlotka, S.; Mukhovskiy, R.; Pietrzykowska, E.; Sobczak, K.; Lojkowski, W. Effect of Water Content in Ethylene Glycol Solvent on the Size of ZnO Nanoparticles Prepared Using Microwave Solvothermal Synthesis. *J. Nanomater.* **2016**, *2016*, 2789871. [[CrossRef](#)]